STOCK TITAN
  1. Home
  2. News
  3. VRCA

Verrica Pharmaceuticals Inc - VRCA STOCK NEWS

Welcome to our dedicated news page for Verrica Pharmaceuticals (Ticker: VRCA), a resource for investors and traders seeking the latest updates and insights on Verrica Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Verrica Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Verrica Pharmaceuticals's position in the market.

News
Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association’s (AAD) 2023 Innovation Academy Meeting
Rhea-AI Summary
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announces the acceptance of an abstract featuring clinical data from the ongoing Phase 2 study of VP-315 for the treatment of basal cell carcinoma (BCC). The presentation will highlight the antitumor efficacy of VP-315 as determined by clinical and histological lesion clearance. The data will be presented at the 2023 American Academy of Dermatology Innovation Academy from August 10-13, 2023, in Tampa, Florida.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
clinical trial
-
News
Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed
Rhea-AI Summary
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) closed a $125 million debt financing with OrbiMed, receiving $50 million upfront and the potential for an additional $75 million based on revenue milestones. The funding will support the commercialization of YCANTH™, FDA-approved for molluscum contagiosum treatment. The five-year term loan bears interest based on the SOFR rate with a margin of 8% per annum. Verrica's cash runway is expected to extend into Q1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.36%
Tags
none
-
News
Following FDA Approval of YCANTH™ for the Treatment of Molluscum Contagiosum, Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8:30 am ET
Rhea-AI Summary
Verrica Pharmaceuticals has entered into a non-binding term sheet for a term loan facility of up to $125 million. The company expects to borrow $50 million immediately following the close of the transaction, with additional capital available based on revenue milestones. The term loan will bear interest at a rate based on the secured overnight financing rate (SOFR), with a floor of 4% and a margin of 8% per annum. The loan facility is expected to extend the company's cash runway into the first quarter of 2025. Verrica also announced that its treatment for molluscum contagiosum, YCANTH, has received FDA approval. The treatment showed positive results in clinical trials, with a significant number of patients achieving complete clearance of molluscum lesions. Verrica plans to make YCANTH available to healthcare providers by September 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.46%
Tags
conferences fda approval
News
Verrica Pharmaceuticals Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum
Rhea-AI Summary
Verrica Pharmaceuticals has received FDA approval for its drug YCANTH™ for the treatment of molluscum contagiosum. The company plans to make the drug available by September 2023. YCANTH™ is a topical solution administered by healthcare professionals and is the first FDA-approved treatment for molluscum. The drug showed positive results in clinical trials, with a significant number of patients achieving complete clearance of lesions. Verrica's President and CEO stated that this approval is a historic moment in medical dermatology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
fda approval
-
News
Verrica Pharmaceuticals Announces Presentation at the Jefferies Healthcare Conference in New York
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.58%
Tags
none
-
News
Verrica Pharmaceuticals Announces Presentation at the RBC Capital Markets Global Healthcare Conference
Rhea-AI Summary
Verrica Pharmaceuticals Inc. announced that Ted White, Verrica President & Chief Executive Officer, will present at the RBC Capital Markets Global Healthcare Conference on May 17, 2023. The event will be held at the InterContinental New York Barclay Hotel and participants can access a live webcast through the provided link. The webcast replay will be available within 24 hours after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
none
News
Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
earnings
-
News
Verrica Pharmaceuticals Announces Dosing of the First Patient in Part 2 of Phase 2 Study Evaluating VP-315 for the Treatment of Basal Cell Carcinoma
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
clinical trial
-
News
Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.49%
Tags
none
News
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
earnings
Stock VRCA logo
Verrica Pharmaceuticals Inc

Nasdaq:VRCA

VRCA Rankings

#3446 Ranked by Market Cap
#576 Ranked by Stock Gains
N/A Ranked by Dividends

VRCA Stock Data

291.42M
15.07M
39.7%
42.59%
9.87%
Medicinal and Botanical Manufacturing
Manufacturing
Link
US
West Chester

About VRCA

verrica pharmaceuticals inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the united states. the company's lead product candidate include vp-102 that is in phase iii clinical trial for the treatment of molluscum contagiosum; in phase ii clinical trial for the treatment of common warts; and completed phase i clinical trial for the treatment of genital warts. it is also developing cantharidin-based product candidate, vp-103 for the treatment of plantar warts. the company has a license agreement with lytix biopharma as to develop and commercialize ltx-315 for dermatologic oncology indications. verrica pharmaceuticals inc. was founded in 2013 and is headquartered in west chester, pennsylvania.